Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The risk for lymphedema (LE) after neoadjuvant chemotherapy (NCT) in breast cancer patients has not been fully understood thus far. This study is conducted to investigate the incidence and time course of LE after NCT. Materials and Methods A total of 313 patients with clinically node-positive breast cancer who underwent NCT followed by surgery with axillary lymph node (ALN) dissection from 2004 to 2009 were retrospectively analyzed. All patients received breast and supraclavicular radiation therapy (SCRT). The determination of LE was based on both objective and subjective methods, as part of a prospective database. Results At a median follow-up of 5.6 years, 132 patients had developed LE: 88 (28%) were grade 1; 42 (13%) were grade 2; and two (1%) were grade 3. The overall 5-year cumulative incidence of LE was 42%. LE first occurred within 6 months after surgery in 62%; 1 year in 77%; 2 years in 91%; and 3 years in 96%. In a multivariate analysis, age (hazard ratio [HR], 1.66; p < 0.01) and the number of dissected ALNs (HR, 1.68; p < 0.01) were independent risk factors for LE. Patients with both of these risk factors showed a significantly higher 5-year cumulative incidence of LE compared with patients with no or one risk factor (61% and 37%, respectively; p < 0.001). The addition of adjuvant chemotherapy did not significantly correlate with LE. Conclusion LE after NCT, surgery, and SCRT developed early after treatment, and with a high incidence rate. More frequent surveillance of arm swelling may be necessary in patients after NCT, especially during the first few years of follow-up.
Abstract
Purpose The risk for lymphedema (LE) after neoadjuvant chemotherapy (NCT) in breast cancer patients has not been fully understood thus far. This study is conducted to investigate the incidence and time course of LE after NCT. Materials and Methods A total of 313 patients with clinically node-positive breast cancer who underwent NCT followed by surgery with axillary lymph node (ALN) dissection from 2004 to 2009 were retrospectively analyzed. All patients received breast and supraclavicular radiation therapy (SCRT). The determination of LE was based on both objective and subjective methods, as part of a prospective database. Results At a median follow-up of 5.6 years, 132 patients had developed LE: 88 (28%) were grade 1; 42 (13%) were grade 2; and two (1%) were grade 3. The overall 5-year cumulative incidence of LE was 42%. LE first occurred within 6 months after surgery in 62%; 1 year in 77%; 2 years in 91%; and 3 years in 96%. In a multivariate analysis, age (hazard ratio [HR], 1.66; p < 0.01) and the number of dissected ALNs (HR, 1.68; p < 0.01) were independent risk factors for LE. Patients with both of these risk factors showed a significantly higher 5-year cumulative incidence of LE compared with patients with no or one risk factor (61% and 37%, respectively; p < 0.001). The addition of adjuvant chemotherapy did not significantly correlate with LE. Conclusion LE after NCT, surgery, and SCRT developed early after treatment, and with a high incidence rate. More frequent surveillance of arm swelling may be necessary in patients after NCT, especially during the first few years of follow-up.
참고문헌 (21)
- DiSipio T, "Incidence of unilateral arm lymphoedema after breast cancer : a systematic review and meta-analysis", Lancet Oncol, 14, pp.500~515 (2013)
- Kim M, "A model to estimate the risk of breast cancer-related lymphedema : combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy", Int J Radiat Oncol Biol Phys, 86, pp.498~503 (2013)
- Shah C, "Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation", Int J Radiat Oncol Biol Phys, 83, pp.1095~1100 (2012)
- Redon CE, "Tumors induce complex DNA damage in distant proliferative tissues in vivo", Proc Natl Acad Sci U S A, 107, pp.17992~17997 (2010)
- Fisher B, "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer : findings from National Surgical Adjuvant Breast and Bowel Project B-18", J Clin Oncol, 15, pp.2483~2493 (1997)
- Lee KS, "A randomized phase-III trial of docetaxel", capecitabine versus doxorubicin, III breast cancer, pp.Breast Cancer Res Treat, 2008[DOI]
- Lee KS, "Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer : a phase II trial", Invest New Drugs, 28, pp.83~90 (2010)
- Huang H, "Secondary lymphoedema after breast cancer surgery : a survival analysis", Int J Nurs Pract, 18, pp.589~594 (2012)
- Coen JJ, "Risk of lymphedema after regional nodal irradiation with breast conservation therapy", Int J Radiat Oncol Biol Phys, 55, pp.1209~1215 (2003)
- Sakorafas GH, "Lymphedema following axillary lymph node dissection for breast cancer", Surg Oncol, 15, pp.153~165 (2006)
- Clark B, "Incidence and risk of arm oedema following treatment for breast cancer : a three-year follow-up study", QJM, 98, pp.343~348 (2005)
- Bevilacqua JL, "Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer", Ann Surg Oncol, 19, pp.2580~2589 (2012)
- Specht MC, "Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients", Ann Surg Oncol, 20, pp.2835~2841 (2013)
- Hayes SB, "Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation?", Int J Radiat Oncol Biol Phys, 72, pp.1449~1455 (2008)
- Warren LE, "The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer : a prospective cohort study", Int J Radiat Oncol Biol Phys, 88, pp.565~571 (2014)
- Norman SA, "Lymphedema in breast cancer survivors : incidence, degree, time course, treatment, and symptoms", J Clin Oncol, 27, pp.390~397 (2009)
- Norman SA, "Risk factors for lymphedema after breast cancer treatment", Cancer Epidemiol Biomarkers Prev, 19, pp.2734~2746 (2010)
- Hayes SC, "Lymphedema after breast cancer : incidence, risk factors, and effect on upper body function", J Clin Oncol, 26, pp.3536~3542 (2008)
- Boughey JC, "Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer : the ACOSOG Z1071(Alliance)clinical trial", JAMA, 310, pp.1455~1461 (2013)
- Daveau C, "Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?", Int J Radiat Oncol Biol Phys, 78, pp.337~342 (2010)
- Le Scodan R, "Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy", Int J Radiat Oncol Biol Phys, 82, pp.1~7 (2012)